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Introduction
Squamous cell carcinoma of the oesophagus is 
the fourth cause of death in males and seventeenth 
in females. There has been no change or a slight de-
crease in incidence over the last three decades, un-
like gastro-oesophageal junction carcinoma, which 
exhibits a constant increase in incidence [1–5]. The 
development of squamous cell carcinoma of the oe-
sophagus and gastro-oesophageal junction leads to 
dysphagia. More than 50% of patients present with 
an unresectable tumour, and progressive weight loss 
and dysphagia require palliative treatment. Among 
the many available methods of palliation, stenting, 
laser therapy, chemoradiation, and photodynamic 
therapy should be considered. However, stenting is 
the method of choice [6–8]. This is because of its 
technical simplicity, wide availability and immediate 
alleviation of dysphagia.
For the first time, in 1885, the prototype of the 
stent was used for intubation of the strictured oe-
sophagus, and rapid development of stenting was 
observed with the development of modern endosco-
py [9]. In the 1970s and 1980s, rigid, semi-rigid and 
plastic stents were used (Photos 1 and 2), associated 
with a high percentage of complications, such as per-
foration, stent migration, and mortality [10]. The in-
troduction of self-expanding metallic stents enabled 
their safe and widespread use. Domschke et al. used 
such a stent for the first time in 1990 [11]. In 1991, 
the modified, silicone-covered Gianturco expandable 
metallic stent was introduced by Song et al. [12]. 
The aim of the present study is to analyse the 
benefits of stents, as well as their disadvantages, 
availability, and novel options of palliative manage-
ment of oesophageal and gastro-oesophageal junc-
tion carcinoma.
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A b s t r a c t
Advanced squamous cell carcinoma of the oesophagus and gastroesophageal junction usually requires palliative 
treatment, and the method of choice is stenting. There are several types of stents currently available, including: 
self-expandable metallic stents (fully or partially covered); self-expandable plastic stents; biodegradable stents. Each 
of the mentioned stents has its advantages and limitations, and requires a proper, patient-tailored selection. Due to 
the close anatomical relationship between the oesophagus and bronchial tree, some patients may require bilateral 
stenting. Oesophageal stenting may not only be considered as a palliative procedure, but can also be implemented 
to alleviate dysphagia during preoperative chemotherapy and/or radiotherapy. 
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Stents
Currently, various stents are commercially avail-
able in Europe, America and Asia, which differ in 
their structure, deployment system, required pre-dil-
atation, coverage, and preparation for introduction. 
In general, stents should be characterised by a thin 
wall, elasticity, easy application, and low complica-
tion rate. Oesophageal stents (Photos 3 and 4) may 
be categorised as follows: 
A. Depending on the coverage (Photos 1, 2): 
1)  partially covered self-expandable stents – e.g. 
Ultraflex, Esopha-Coil, Flamingo, Gianturco 
Z-stent, Evolution;
2)  fully covered self-expandable stents – e.g. Ali-
maxx-E, Niti-S, SX-Ella, Wallflex, Polyflex.
B. Depending on the material used: 
1)  nitinol – e.g. Ultraflex, Esopha-Coil, Wallflex, 
Niti-S, Choo, Hanaroo, Evolution, Alimaxx-E;
2)  steel – e.g. Gianturco Z-stent, Flamingo, Wall-
stent II;
3)  plastic – e.g. Polyflex.
4)  polydioxanone – e.g. Ella (Photo 3).
C. Depending on function: 
1)  with an anti-reflux valve – e.g. Ella, Dostent;
2)  with an anti-migration mechanisms – e.g. Ali-
maxx.
D. Depending on release: 
1) distal – e.g. Ultraflex;
2) proximal – e.g. Ultraflex.
The introduction of self-expanding metallic 
stents (SEMS) resulted in the elimination of rigid 
prostheses, which were associated with high in-
cidence of severe complications. Covered stents 
constitute the largest and most commonly used 
Photo 1. Uncovered and partially covered self- 
expanding metal stents (PCSEMS) from left to 
right: Ultraflex (uncovered) (Boston Scientific) 
Ultraflex (partial covered) (Boston Scientific), 
Evolution (Cook)
Photo 2. Fully covered self-expanding metal stents (FCSEMS) and partial covered self-expanding metal 
stents (PCSEMS) from left to right: Wallflex (Boston Scientific), Evolution (Cook), Niti-S double oesophageal 
stent (Taewoong), Niti-S Beta 2 (Taewoong) Niti-S S oesophageal stent (Taewoong), Flexella Plus (Ella), Evo 
– PCSEMS (Cook), Alimaxx ES (Endotek)
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group. While uncovered SEMS were characterised 
by neoplastic tissue ingrowth, very difficult or im-
possible removal and difficult repositioning after 
implantation, the partially covered SEMS are as-
sociated with a much lower rate of these compli-
cations. They are, however, not free of problems, 
such as hypertrophic granulation of the proximal 
or distal end, leading to occlusion, migration, and 
fistula development [13].
The introduction of fully covered self-expand-
ing stents in 2001 did not solve all problems. These 
stents are characterised by difficult implantation, 
due to their plastic construction. They have to be 
introduced through a guide, which is rigid, approxi-
mately 10 mm in diameter, and not always arranged 
in a manner suited to the intended site of implan-
tation. These stents are also characterised by a ten-
dency for migration.
Absorbable stents are a  relatively new alterna-
tive for patients with oesophageal carcinoma. These 
stents may be used in the preoperative period, since 
their functioning is limited by the absorption time of 
~12 weeks. They are made of an absorbable materi-
al – PDS. Their potential advantage is based on the 
possibility of absorption, although implantation re-
quires wide oesophageal patency restoration, which 
limits the use of absorbable stents.
An oesophageal stent may be applied after neoplas-
tic stricture dilatation (up to the diameter of 10 mm). 
Commercially available oesophageal stents may be 
introduced under radiological or endoscopic con-
Photo 3. Fully covered plastic prosthesis on the 
left side: Polyflex (Boston Scientific) and SX Ella 
degradable (Ella) prosthesis on the right side for 
treatment of benign and malignant oesopha-
geal stricture
Photo 4. Types of prosthesis for oesophago-gastric junction cancer stenting, from left to right: Flamingo 
stent – PCSEMS (Boston Scientific), Cardia-Umbrella – FCSEMS (Micro-Tech), Cardia-Valve-stent – FCSEMS 
(Micro-Tech), Dua antireflux “wind sock” – PCSEMS (Cook), Boubella-E antireflux valve (FCSEMS) (Ella), 
Niti-S double anti-reflux valve (FCSEMS) (Taewoong)
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trol, and therefore are equipped with markers, eas-
ily identified on the fluoroscopy image. Endoscopic 
clips can also be used to mark the area of dilatation. 
Clinical evaluation
Oesophageal stenting is the method of choice in 
palliative management, but specific types of stents 
may also be used in cases of benign strictures and 
iatrogenic oesophageal perforations with mediasti-
nitis [14]. 
The main indications for palliative oesophageal 
stenting include:
–  dysphagia due to the inoperable oesophageal can-
cer;
–  oesophageal compression due to mediastinal dis-
eases (Hodgkin’s disease, non-Hodgkin’s lympho-
ma, inoperable lung cancer);
–  small cell lung cancer infiltrating the oesophagus;
–  thyroid cancer.
Patients requiring stenting are usually diagnosed 
with grade III and IV dysphagia and significant 
weight loss. It should also be remembered that these 
patients may require bronchial tree stenting, due 
to the close anatomical relationship between the 
oesophagus and bronchial tree (trachea and main 
bronchus). Therefore, during the endoscopic exam-
ination, the bronchial tree should also be assessed, 
especially when the neoplastic infiltration is locat-
ed ~25 cm from the incision. In patients diagnosed 
with locally advanced cancer, compression of the left 
main bronchus and/or tracheal bifurcation may be 
observed, as well as oesophago-respiratory fistula. 
Deployment of the stent within the oesophagus may 
exacerbate compression of the airway and lead to 
acute asphyxia. Therefore, oesophageal stenting in 
such patients requires the preparation of the team 
to perform, if necessary, simultaneous bronchial tree 
stenting [15]. If this is anticipated on the basis of CT 
scan, airway stenting should be performed first. 
Oesophageal dilatation
Patients with grade III and IV dysphagia require 
stricture dilatation before the stenting procedure. 
The dilatation technique in cases of oesophageal 
strictures varies among centres. 
Generally, three methods of dilatation can be dis-
tinguished [16]:
1)  mercury-filled rubber dilators – e.g. Maloney or 
Hurst;
2)  guided polyvinyl dilators – e.g. Savary-Gilliard, 
Eder-Puestow, Celestin, Beuss, Biomed System 
American;
3)  hydrostatic polyurethane balloons – e.g. TTS 
(through-the-scope), Rigiflex, Medi-Tech.
Mercury-filled rubber dilators are nowadays rare-
ly used and have a  mainly historical importance. 
They are most commonly employed in cases of short 
and medium-sized stricture dilatations. Wire-guided 
dilators are most commonly used. This is associated 
with their relative safety, ‘tactile sensitivity’ during 
the procedure, and low rate of complications. 
Pneumatic balloon dilators are also very popular. 
The method is characterised by a  low perforation 
rate. When using balloon dilators, there is no tactile 
control over stricture dilatation.
Oesophageal stent characteristics
Oesophageal stenting has been developing since 
the 1970s, when rigid stents were introduced by Wil-
son-Cook. Due to implantation difficulties and ma-
terial quality, their use was associated with a high 
percentage of complications, especially oesophageal 
perforation, bronchial tree fistula formation, and 
a  mortality rate of up to 10%. They were subse-
quently replaced by steel wire prostheses, which had 
fewer complications, although tumour ingrowth was 
an important drawback. Nowadays, fully or partially 
covered prostheses are used. These are character-
ised by a low complication rate [17]. 
The ideal prosthesis should have the following 
characteristics:
–  appropriate diameter enabling full oral nutrition 
without obstruction after meals;
–  low risk of migration, granulation tissue stent 
overgrowth, bleeding, and fistula formation;
–  flexibility;
–  technical simplicity of implantation, reposition, 
and removal; 
–  low risk of regurgitation.
The Ultraflex stent (Boston Scientific, Natick, 
USA) is made of nitinol, and fully or partially covered. 
It is highly flexible. These stents are also available 
without covering. Depending on the model, they 
have either proximal or distal release systems and 
facilitate precise implantation without fluoroscopic 
guidance, under simple endoscopic control. After im-
plantation, they shorten by up to 30%. The new gen-
eration of these fully or partially covered stents are 
silicone-covered nitinol prostheses. In contrast to 
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those mentioned above, they can be refolded if dila-
tation amounts to 75%. This stent is equipped with 
‘progressive step flared ends’, preventing migration. 
Gianturco Z-stents (Cook, Winston Salem, USA) 
are partially covered steel-wire prostheses, available 
with an anti-reflux valve.
The Evolution stent (Cook, Winston Salem, USA) is 
a nitinol, partially covered prosthesis. The stent is dis-
tally dilated with recapture possibility, prior to full dil-
atation (in case of 50% dilatation). The stent contains 
an inner and outer membrane, which is intended to 
prevent granulation tissue ingrowth and to facilitate 
food passage. It has an anti-migration mechanism in 
the form of uncoated flanges on both ends. 
Alimaxx-E (Alveolus, Charlotte, NC, USA) is a ful-
ly silicone covered, nitinol stent. The prostheses are 
laser-cut from a nitinol tube, and have an anti-reflux 
mechanism in the form of ‘fish scales’. Fluoroscopy is 
not required. An interesting solution was proposed in 
cases of gastro-oesophageal junction cancer stents – 
the cardia umbrella stent. Due to its umbrella design, 
this nitinol, fully covered prosthesis has the ability to 
adjust to the cardia area, preventing displacement.
Niti-S (Taewong Medical, Seoul, Korea) is a ‘dou-
ble stent’, with a non-covered external layer intend-
ed to prevent migration and a  silicone-covered in-
ternal layer preventing granulation tissue ingrowth. 
Choo-stent (M.I. Tech Medical, Seoul, Korea) is 
a nitinol, fully covered prosthesis, polyurethane-coat-
ed, distally released. An anti-reflux valve option is 
possible. 
SX-Ella (Ella-CS, Hradec Kralove, Czech Republic) 
is a fully covered nitinol or steel prosthesis, distally 
released, with an anti-reflux valve and proximal pole 
ring preventing migration. 
Biodegradable stents (Ella-CS, Hradec Kralove, 
Czech Republic) are non-covered prostheses made 
of PDS with a 12-week period of absorption. They 
are recommended during chemo-radiotherapy, prior 
to planned surgery, and in cases of benign lesions. 
The mechanism of implantation allows for multiple 
use. Prior to implantation, the stricture should be 
dilated to 12–14 Fr values; the rigidity of the guide 
and its location do not always allow for convenient 
stent dilatation.
Oesophageal stenting results  
and complications 
The aim of stenting in patients with inoperable 
or unresectable oesophageal cancer is to obtain 
oesophageal patency and complete oral nutrition. 
The development of endoscopy and technological 
progress currently enable the use of a number of oe-
sophageal stents. The main characteristics include: 
safety and simplicity of implantation, bioelasticity, 
shape memory deployment, matching the shape of 
the stricture, resistance to deformation, and biode-
gradability [18]. Currently, steel, nitinol, cobalt, and 
an absorbable PDS polymer are used. 
The procedure lasts a  relatively short time, ap-
proximately 30 min, with a  technical success rate 
reaching 100%. It is recommended to cover with the 
stent ~4 cm of the oesophagus above and below the 
stricture, although this is not always possible, espe-
cially in cases of proximal strictures [19]. Currently, 
with the fully covered plastic prostheses, stenting of 
the cervical oesophagus is also possible. Stent im-
plantation is associated with low perioperative mor-
tality ranging from 0 to 5%, while 30-day mortality 
ranges between 7% and 18% [20–25].
The stents that are currently used, despite rel-
ative good tolerance, are not free from side-effects 
and complications. One of the most common com-
plications associated with stenting is granulation 
tissue overgrowth. Coverage with a polyurethane or 
silicone membrane protects from tumour ingrowth, 
but overgrowth beyond the ends of the stent and 
granulation tissue formation remain an issue. Gran-
ulation tissue is observed within two months after 
stent implantation in 47% of patients [26–30]. This 
problem, although rarely, is encountered also with 
fully covered plastic stents [31, 32]. The cause of 
granulation tissue overgrowth remains unknown. 
Stents of a diameter smaller than 20 mm overgrow 
much more slowly (SX Ella stent, Polyflex, Niti-S and 
Gianturco Z-stent) [33].
Another important complication associated with 
oesophageal stents is migration. It is usually ob-
served in 20% of cases and it more often concerns 
fully covered plastic stents, as compared to those 
partially covered. Verschuur et al. demonstrated that 
Ultraflex stent migration was observed in 17% of 
patients, while Polyflex stent migration in 29%. Ad-
ditionally, stents with an anti-migration mechanism 
(SX Ella, Niti-S, Alimaxx) do not always effectively 
prevent this complication [24, 28].
Fistulas to the bronchial tree are late, life-threat-
ening complications. They occur in 10% of patients 
after stenting. Ferreira et al. observed their occur-
rence in 7 of 126 patients, while Uitdehaag et al. 
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observed them in 2 out of 4, after the use of SX Ella 
stents [29, 34, 35].
Bleeding after stenting is another life-threaten-
ing complication, and it reportedly occurs in 2–28% 
of patients [34, 36, 37].
Other, less severe complications include chest 
pain, foreign body sensation, and regurgitation. 
When considering the above-mentioned stents, no 
evidence of superiority of any of the prostheses was 
observed [23].
Gastro-oesophageal junction stenting 
Gastro-oesophageal junction cancer stenting, 
as compared to proximal oesophageal stenting, is 
characterised by certain peculiarities and a  higher 
complication rate. Stent migration is the most com-
mon complication. It is associated with fixation of 
the proximal end of the stent only – its distal seg-
ment being located in the stomach. Such a location 
also favours bleeding after stent placement. Siers-
ma et al. connected this with two factors. First, the 
free segment of the stent assumes a forced position, 
pressing against the posterior wall of the oesoph-
agus, which leads to its damage, ulceration, and 
bleeding. Secondly, the forced position of the stent, 
determined by the anatomy of the angle between 
the oesophagus and cardia, leads to exacerbation of 
reflux and worse swallowing quality [38, 39]. Vakil 
et al., in a  randomised study, observed migration of 
the stent placed across the cardia in 12% of cases [40].
It appears that the type of stent, especially its 
proximal diameter (flange diameter: Flamingo Wall-
stent – 30 mm, Wallstent II – 28 mm and Ultraflex 
– 28 mm), may play an important role in prevent-
ing migration. However, other studies showed that 
a  larger stent diameter led to an increased rate of 
perforations and bleeding [33, 41, 42].
Vakil et al. demonstrated migration in 12% of 
cases, while the overall complication rate was 30%. 
Other most common complications include: fever, 
not necessarily associated with aspiration pneumo-
nia, chest pain, granulation tissue overgrowth, food 
bolus obstruction, and perforation. No evidence of 
superiority of any of the stents was observed, when 
considering complications after stenting of the car-
dia [38, 43].
It is believed that adjuvant chemo- and/or radio-
therapy may increase the proportion of complica-
tions. It should be remembered that dysphagia may 
persist in a subset of patients following proper stent 
implantation, due to peritoneal metastases causing 
mechanical obstruction.
Quality of life
Quality of life is one of the most important factors 
of effective palliative treatment. Among the many 
questionnaires, the EORTC QLQ-C30 protocol is most 
often used. With 30 questions, it assesses the phys-
ical and emotional functioning, grade of dysphagia, 
nausea, vomiting, gastric content regurgitation, pain, 
degree of anxiety, and depression. The assessment of 
dysphagia is the key element considering the quality 
of life in patients with oesophageal carcinoma [44, 45].
Conclusions
Oesophageal metallic stents remain the gold 
standard in the palliative treatment in advanced 
squamous cell carcinoma of the oesophagus. Partial-
ly and fully covered stents are highly useful and well 
accepted. New stent designs and evolution of mate-
rials have reduced complication rates after stenting 
and increased the effectiveness and safety of palli-
ative therapy. It should be remembered that some 
patients require bilateral stenting of the oesophagus 
and bronchial tree.
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